News
- Author:
- Bruce Jancin
Publish date: January 18, 2018
DENVER – MITRAL trial breaks new ground for formerly no-hope patients.
News
- Author:
- Bruce Jancin
Publish date: January 18, 2018
There is cautious optimism that selective use of endovascular therapies for mesenteric venous thrombosis improves outcomes.
News
- Author:
- Bruce Jancin
Publish date: January 17, 2018
CAS isn’t associated with a lower 30-day stroke risk than CEA for revascularization in patients with contralateral carotid occlusion.
News
- Author:
- Bruce Jancin
Publish date: January 16, 2018
DENVER – Evolut R valve performs favorably off-label in registry.
News
- Author:
- Bruce Jancin
Publish date: January 16, 2018
CHICAGO – Work compression – a key driver of burnout and depression – is especially common in vascular surgery.
News
- Author:
- Bruce Jancin
Publish date: January 16, 2018
DENVER – For STEMI, 6 months was as good as 12 in “hypothesis-generating” RCT.
News
- Author:
- Bruce Jancin
Publish date: January 16, 2018
PARIS – Relapse-free predictors are older age, more psychotic symptoms, and early ECT response.
News
- Author:
- Bruce Jancin
Publish date: January 9, 2018
GENEVA – “We struggle with these patients, maybe more so than with our psoriasis and atopic dermatitis patients.”
News
- Author:
- Bruce Jancin
Publish date: January 9, 2018
GENEVA – This skin eruption is “underdiagnosed and overtreated” in SLE patients.
News
- Author:
- Bruce Jancin
Publish date: January 9, 2018
DENVER – Why experts predict the impressive results won’t change U.S. practice.
News
- Author:
- Bruce Jancin
Publish date: January 8, 2018
GENEVA – The X-ACT study spotlights profound quality-of-life impairment in patients with chronic spontaneous urticaria.
News
- Author:
- Bruce Jancin
Publish date: January 8, 2018
GENEVA – Ixekizumab works “extraordinarily well” for psoriasis – even with prior exposure to other IL-17 inhibitors.
News
- Author:
- Bruce Jancin
Publish date: January 8, 2018
GENEVA –Three-quarters of nonresponders to approved dose achieve disease control at 450 mg to 600 mg.
News
- Author:
- Bruce Jancin
Publish date: January 4, 2018
DENVER – Meta-analysis shows 55% fewer disabling strokes with the left atrial appendage closure device, compared with warfarin.
News
- Author:
- Bruce Jancin
Publish date: January 2, 2018
PARIS – Neuroimaging morphs into neurotherapy in proof-of-concept study.
